HER2 Low Breast Cancer: New Clinical Entity or Testing Artifact
Should breast cancer patients with low but not negative tumor expression of HER2 be considered a distinct patient group that can be treated differently from patients with tumors that are HER2 negative or HER2 positive? That was the question posed during a session at the recent San Antonio Breast Cancer Symposium (SABCS) 2022.Source: Medscape
Glazer and Omer Are New Members of National Academy of Medicine
Two Yale faculty members, Peter M. Glazer, MD, PhD; and Saad B. Omer, MBBS, MPH, PHD; have been elected to the prestigious National Academy of Medicine, the academy announced today. Founded in 1970 as the Institute of Medicine the National Academy of Medicine (NAM) is one of three academies that make up the National Academies of Sciences, Engineering, and Medicine (the National Academies) in the United States.
Juan Vasquez, MD, Vidya Puthenpura, MD, MHS, FAAP, Awarded Grants to Further Pediatric Cancer Research
Two rising young stars of pediatric cancer research at Yale Cancer Center and Yale School of Medicine were awarded research grants from Hyundai Hope on Wheels program to further their work of improving outcomes and treatment for children diagnosed with cancer.
Fighting Breast and Ovarian Cancer With a Lupus Antibody
After discovering a specific lupus antibody that can penetrate cancer cells and, with a grant from Women's Health Research at Yale, showing it makes cancer cells vulnerable to standard treatments, Dr. Peter Glazer and his colleagues are moving a treatment to clinical trials.
Sex Differences in Gastrointestinal Cancer
With this year's Wendy U. and Thomas C. Naratil Pioneer Award and co-funding from the Yale Cancer Center, Dr. Pamela Kunz is conducting one of the first studies to examine sex differences in treating neuroendocrine neoplasms (NENs), a rare form of cancer often found in the gastrointestinal tract.
Yale Cancer Center Researchers Awarded Grants by Breast Cancer Research Foundation
The Breast Cancer Research Foundation (BCRF) Scientific Advisory Board and its Board of Directors recently announced its 2022 research grants, including six funded grants at Yale Cancer Center and Smilow Cancer Hospital awarded to Mehra Golshan, MD, MBA, Melinda Irwin, PhD, MPH, Ian Krop, MD, PhD, Lajos Pusztai, MD, DPhil, David Rimm, MD, PhD, and Eric Winer, MD to support their research.
Yale Cancer Center Partners in Fight to Help Eliminate HPV-related Cancers
Yale Cancer Center joins the Association of American Cancer Institutes (AACI) and its partner organizations to endorse a Call to Action for our nation to work together toward the elimination of human papillomavirus (HPV)-related cancers.
Yale Cancer Center scientists discover molecular key to how cancer spreads
Yale Cancer Center researchers have discovered how metastasis, the spread of cancer cells throughout the body, is triggered on the molecular level, and have developed a tool with the potential to detect those triggers in patients with certain cancers. The discovery could lead to new ways for treating cancer.
Alessandro Santin Recognized as 2019 ASCO Leader in Cancer Care
Research by Alessandro Santin, M.D., professor of gynecology, obstetrics & reproductive sciences and leader of the Disease Aligned Research Team of the Gynecologic Oncology Program at Smilow Cancer Hospital and Yale Cancer Center, has had his research selected as one of the top five advances of the year by the American Society of Clinical Oncology (ASCO).
Yale Study Finds Link Between Medicaid Expansion and Equity in Cancer Care
Racial disparities in timely cancer treatment disappeared in states that expanded Medicaid under the Affordable Care Act (ACA), according to an analysis of over 30,000 health records led by researchers at Yale Cancer Center. The findings were presented at the American Society of Clinical Oncology (ASCO) 2019 annual meeting.
A Successful Form of Immunotherapy For Blood Cancers Shows Promise For Other Types of the Disease
An innovative new immunotherapy treatment at the Yale Cancer Center and Smilow Cancer Hospital called CAR T-cell therapy has shown remarkable success in treating certain blood cancers, including some for which all other treatment options have failed.Source: Connecticut Magazine
Yale Study Identifies How Cancer Drug Inhibits DNA Repair in Cancer Cells
Yale Cancer Center researchers have found that a cancer drug thought to be of limited use possesses an unforeseen property. It is able to stop certain cancer cells from repairing their DNA in order to survive. The study suggests that combining this drug, cediranib, with other agents could potentially deliver a lethal blow in cancer that uses a specific process to create DNA repair cells.
National Cancer Center Partnership Expected to Advance Cancer Research at YSPH, Yale
A new partnership with the National Cancer Center of China will provide opportunities for collaborative research, clinical trials and workforce training at the Yale School of Public Health, Yale Cancer Center and Yale Institute for Global Health.
Yale Cancer Center Scientists Receive Grant to Advance Lung Cancer Research
Katerina Politi, PhD and Don Nguyen, PhD, members of the Signal Transduction Research Program at Yale Cancer Center (YCC), have received a 5-year, nearly $4 million National Cancer Institute (NCI) grant to support Lung Cancer research.
Smilow Cancer Hospital and Yale Cancer Center receive grant from Frederick A. DeLuca Foundation to fund Hematology Research Center
Yale Cancer Center (YCC) and Smilow Cancer Hospital (SCH) are proud to announce a five-year grant awarded by The Frederick A. DeLuca Foundation to establish The DeLuca Center for Innovation in Hematology Research.
Iwasaki Is Honored by the International Cytokine & Interferon Society
Akiko Iwasaki, PhD, Waldemar Von Zedtwitz Profesor of Immunobiology and Molecular, Cellular, and Developmental Biology; and professor of dermatology, is a 2019 recipient of the Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research, given by the International Cytokine & Interferon Society (ICIS).
Complex cancer surgery is safer at brand name cancer hospitals compared to the affiliate hospitals that share their brand
A new study by Yale Cancer Center (YCC) researchers shows complex cancer surgery is safer at brand name cancer hospitals than at affiliated hospitals that share the top-notch brand names.